Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing
1–17
Headlines
17
Sources here
10
Companies here
1
Current section Japan Drug Manufacturers - Specialty & Generic news

Takeda Pharmaceutical (TSE:4502) Wins ORZEYFUL Approval, Where Does Fair Value Sit?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Takeda Pharmaceutical (TSE:4502) has drawn fresh attention after U.S. regulators approved ORZEYFUL for adult narcolepsy type 1, and the company also issued new impairment …

4502 main company
Sharemaestro market context Price above Trend Line 52 weeks +30.8% 4502 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Takeda CSO Chris Arendt on Transforming Drug Discovery & the R&D Pipeline

Takeda is entering one of the most pivotal moments in its 245-year history, with a late-stage pipeline poised to transform patient outcomes across three therapeutic areas. Chief Scientific Officer Chris Arendt goes Inside the ICE House to discuss the science behind drug candidates targeting …

4502 main company
Sharemaestro market context Price above Trend Line 52 weeks +30.8% 4502 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Chronological news

Latest headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum

Denali Therapeutics DNLI reported a second-quarter 2026 loss of 68 cents per share, narrower than the Zacks Consensus Estimate of a loss of 73 cents. The company incurred a loss of 72 cents in the year-ago quarter. In late March, Denali secured a major …

4502 mentioned
Sharemaestro market context Price above Trend Line 52 weeks +30.8% 4502 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context